The strategic collaboration agreement grants AstraZeneca the exclusive right to import, distribute and promote OM Pharma’s Broncho-Vaxom (Bacterial Lysates - OM-85) in China (excluding Hong Kong, Macau, and Taiwan).
Broncho-Vaxom is a therapeutic agent that effectively prevents and treats recurrent or acute respiratory infections in adult and pediatric patients by boosting the host immunity. In China, recurrent respiratory tract infection is a common disease in pediatrics, with an incidence rate of about 20%. The prevalence of COPD among people over 40 years old is 8.2%. The acute exacerbation of COPD occurs about 0.5 to 3.5 times per year, and is an important factor in COPD deaths.
Leveraging Both Parties’ Expertise
This long-term collaboration will fully leverage both parties’ expertise and provide more effective treatment options for patients in China. The safety profile and clinical benefits of Broncho-Vaxom have been proven by a large body of clinical evidence.
Josef Troxler, CEO of OM Pharma, commented, “Broncho-Vaxom is one of OM Pharma’s flagship products. The product has been used for a long time in clinical settings for the prevention of respiratory infections and immunological conditions. This highly synergistic collaboration between OM Pharma and AstraZeneca will improve the accessibility of Broncho-Vaxom, accelerate the product’s growth in the Chinese market, and further solidify OM Pharma’s lead in the field of respiratory diseases and immunological therapies.”
Michael Lai, general manager of AstraZeneca China, added, “AstraZeneca has been deeply rooted in China for 27 years. Staying true to our patient-centric mission, we continue to focus our efforts on the therapeutic areas with the most urgent medical needs and on providing high quality medicines for patients. Respiratory & Immunology are key areas of focus for AstraZeneca China. We hope to broaden and deepen the market penetration of Broncho-Vaxom to improve the health of more patients in need.”